China SXT Current Valuation vs. Cash And Equivalents
| SXTC Stock | USD 0.38 0.01 2.56% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.48 | 0.2873 |
|
|
For China SXT profitability analysis, we use financial ratios and fundamental drivers that measure the ability of China SXT to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well China SXT Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between China SXT's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of China SXT Pharmaceuticals over time as well as its relative position and ranking within its peers.
China |
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.57) | Revenue Per Share 2.223 | Quarterly Revenue Growth 0.295 | Return On Assets (0.05) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
China SXT Pharmaceuticals Cash And Equivalents vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining China SXT's current stock value. Our valuation model uses many indicators to compare China SXT value to that of its competitors to determine the firm's financial worth. China SXT Pharmaceuticals is rated second in current valuation category among its peers. It is currently regarded as top stock in cash and equivalents category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China SXT's earnings, one of the primary drivers of an investment's value.China Current Valuation vs. Competition
China SXT Pharmaceuticals is rated second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Consumer Staples industry is at this time estimated at about 12.46 Billion. China SXT has negative current valuation of (7.87 Million) having no influence on the industry.
China Cash And Equivalents vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
China SXT |
| = | (7.87 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
China SXT |
| = | 15.52 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
China Cash And Equivalents Comparison
China SXT is currently under evaluation in cash and equivalents category among its peers.
China SXT Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in China SXT, profitability is also one of the essential criteria for including it into their portfolios because, without profit, China SXT will eventually generate negative long term returns. The profitability progress is the general direction of China SXT's change in net profit over the period of time. It can combine multiple indicators of China SXT, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1 M | -974.5 K | |
| Interest Income | 4.7 K | 4.4 K | |
| Operating Income | -2.5 M | -2.4 M | |
| Net Loss | -3.1 M | -3.3 M | |
| Income Before Tax | -3.1 M | -3.3 M | |
| Total Other Income Expense Net | -583.3 K | -612.5 K | |
| Net Loss | -5.2 M | -4.9 M | |
| Net Loss | -3.1 M | -3.3 M | |
| Income Tax Expense | 3.00 | 2.85 | |
| Net Interest Income | -544.3 K | -571.5 K | |
| Change To Netincome | 4.3 M | 4.5 M | |
| Net Loss | (3.57) | (3.75) | |
| Income Quality | 0.62 | 0.53 | |
| Net Income Per E B T | 0.95 | 0.70 |
China Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on China SXT. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of China SXT position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the China SXT's important profitability drivers and their relationship over time.
Use China SXT in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if China SXT position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China SXT will appreciate offsetting losses from the drop in the long position's value.China SXT Pair Trading
China SXT Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to China SXT could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China SXT when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China SXT - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China SXT Pharmaceuticals to buy it.
The correlation of China SXT is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China SXT moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China SXT Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for China SXT can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your China SXT position
In addition to having China SXT in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Social Domain Thematic Idea Now
Social Domain
New or established large and mid-sized companies that are involved in the social media industry, including entities that provide web-based or mobile media applications and services across across large segment of population in multiple geographical areas. The Social Domain theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Social Domain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project China SXT's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of China SXT Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include China SXT's income statement, its balance sheet, and the statement of cash flows.